SBIO news

ALPS Medical Breakthroughs · United States

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

wallstreet:online · 27 Oct 2026, 20:05 UTC
Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
3.9% of SBIO
Seeking Alpha · 27 Oct 2026, 07:31 UTC
CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy (NASDAQ:CGON) | Seeking Alpha
3.4% of SBIO
24/7 Wall St. · 28 Oct 2026, 16:04 UTC
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
1.1% of SBIO
Investing.com · 27 Oct 2026, 09:44 UTC
Why is Dianthus Therapeutics stock gaining today? By Investing.com
2.6% of SBIO
Where to buy SBIO
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
wallstreet:online · 26 Oct 2026, 12:00 UTC
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva
3.9% of SBIO
wallstreet:online · 26 Oct 2026, 20:35 UTC
Travere Therapeutics to Report Third Quarter 2026 Financial Results
2.8% of SBIO
Where to buy SBIO
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Seeking Alpha · 27 Oct 2026, 23:03 UTC
Zai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer - Slideshow (NASDAQ:ZLAB) 2026-10-27 | Seeking Alpha
1.3% of SBIO
Markets Insider · 27 Oct 2026, 01:37 UTC
BTIG Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)
1.8% of SBIO
Markets Insider · 25 Oct 2026, 21:45 UTC
Celcuity announces results from PIK3CA cohort of Phase 3 VIKTORIA-1
3.9% of SBIO
Benzinga · 28 Oct 2026, 17:55 UTC
Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth - Geron (NASDAQ:GERN)
0.5% of SBIO
Market Screener · 26 Oct 2026, 20:20 UTC
Oruka Therapeutics, Inc. Announces Positive Week 16 Results for Orka-001 from the Ongoing Everlast-B Trial in Moderate-To-Severe Psoriasis
1.8% of SBIO
Seeking Alpha · 26 Oct 2026, 16:50 UTC
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis - Slideshow (NASDAQ:ORKA) 2026-10-26 | Seeking Alpha
1.8% of SBIO
Seeking Alpha · 26 Oct 2026, 16:49 UTC
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript | Seeking Alpha
1.8% of SBIO
Benzinga · 26 Oct 2026, 16:45 UTC
Oruka Therapeutics Stock Soars - Here's Why - Oruka Therapeutics (NASDAQ:ORKA)
1.8% of SBIO
Investing.com · 28 Oct 2026, 12:29 UTC
Why is Geron stock sliding today? By Investing.com
0.5% of SBIO
Investing.com · 28 Oct 2026, 12:26 UTC
Geron stock tumbles after halting Phase 3 trial By Investing.com
0.5% of SBIO
The Manila times · 28 Oct 2026, 12:13 UTC
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
0.5% of SBIO
RTTNews · 26 Oct 2026, 15:14 UTC
Oruka Therapeutics Stock Jumps 12% After Positive Phase 2b Psoriasis Trial
1.8% of SBIO
Benzinga · 26 Oct 2026, 14:23 UTC
Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday - EQT
1.8% of SBIO
Investing.com · 26 Oct 2026, 14:20 UTC
Why is Oruka Therapeutics stock surging today? By Investing.com
1.8% of SBIO

SBIO news

Where to buy SBIO

Where to buy SBIO